Article Text

Download PDFPDF
Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis
  1. Y Levy1,
  2. Y Uziel4,
  3. G G Zandman1,2,
  4. H Amital1,
  5. Y Sherer1,
  6. P Langevitz2,
  7. B Goldman3,
  8. Y Shoenfeld1
  1. 1Department of Medicine B and the Centre for Autoimmune Diseases, Sheba Medical Centre Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Israel
  2. 2Rheumatic Diseases Unit, Sheba Medical Centre Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Israel
  3. 3Institute of Genetics, Sheba Medical Centre Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Israel
  4. 4Paediatric Rheumatology Unit, Sapir Medical Centre, Kfar Saba, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  1. Correspondence to:
    Professor Y Shoenfeld
    Department of Medicine “B”, Sheba Medical Centre, Tel-Hashomer, 52621, Israel; shoenfelpost.tau.ac.il

Abstract

Background: Peripheral neuropathy is a prominent feature of the systemic and secondary vasculitides. Usually, it is responsive to corticosteroids, but in certain cases it may be resistant to corticosteroid or immunosuppressive treatment, or both.

Objective: To present patients who exhibited various inflammatory diseases accompanied with vasculitic peripheral neuropathies for which intravenous immunoglobulin (IVIg) was used for treatment.

Methods: Six patients with Sjögren’s syndrome, systemic lupus erythematosus (SLE), vaccination induced vasculitis, Churg-Strauss vasculitis, mixed cryoglobulinaemia associated with hepatitis C infection, or sarcoidosis were included. All developed vasculitic peripheral neuropathy, and were treated with high dose IVIg (2 g/kg body weight). The patients were followed up for 1–5 years after this treatment.

Results: In four patients (Sjögren’s syndrome, Churg-Strauss vasculitis, SLE, and vaccination induced vasculitis) the neuropathy resolved after IVIg treatment.

Conclusion: IVIg may be beneficial in cases of resistant vasculitic peripheral neuropathy. IVIg should probably be considered as a sole or adjuvant treatment for patients with contraindications to conventional treatment, or alternatively, for patients in whom conventional treatment has failed.

  • peripheral neuropathy
  • vasculitis
  • immunoglobulins
  • EMG electromyography
  • IVIg, intravenous immunoglobulin
  • SLE, systemic lupus erythematosus
  • SS, Sjögren’s syndrome

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes